Author:
Shen Yang,Shen Zhixiang,Jiang Bin,Hou Jian,Zhan Rong,Qiu Lugui,Zhou Daobin,Jin Jie,Li Juan,Meng Fanyi,Zou Ping,Liu Ting,Li Jianyong,Wang Chun,Wu Depei,Ma Jun
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Munshi NC, Tricot G, Barlogie B. Plasma cell neoplasms. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology; Vol 2. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005.
2. Terpos E, Rahemtulla A, Dimopoulus MA. Current treatment options for myeloma. Expert Opin Pharmacother 2005; 6: 1127–1142.
3. Hussein MA. Thalidomide: present and future in multiple myeloma. Expert Rev Anticancer Ther 2005; 5: 25–31.
4. Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989; 14: 882–885.
5. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86–89.